BASF introduces new solutions for the personal care market
![](/46/pdcnewsitem/07/54/44/GettyImages-157641196.jpg)
Wax-based and readily biodegradable: Euperlan OP White and Cegesoft Peel.
At SCS Formulate on 13 & 14 November in Coventry, BASF will share stand 500 with its European distribution organization BTC Europe and present the latest solutions to meet the demands of the personal care market.
Readily biodegradable, wax-based opacifier dispersion and exfoliating beads for personal care products
BASF Care Creations will showcase two new products that answer the needs of today’s environmentally conscious consumers. “We are constantly seeking innovative and more sustainable solutions for the personal care industry. Consumer trends and needs clearly show us the way. With our new ingredients Euperlan OP White and Cegesoft Peel we can help our customers to develop winning products supporting both the consumers’ well-being and eco-conscience,” said Dirk Mampe, Vice President Business Management Personal Care Solutions Europe.
Euperlan OP White is a wax-based, readily biodegradable and cold processable opacifier dispersion with a superior white appearance for surfactant formulations. The product meets today’s demand for ecological friendly ingredients and its unique properties make it particularly suitable for eco-label conforming skin and hair cleansing formulations. BASF is the leading supplier of cold processable wax dispersions for personal care that provide optical effects in rinse off products. Euperlan OP White complements BASF’s current portfolio of pearlizing wax dispersions and can be used as an alternative to synthetic polymeric opacifiers.
Cegesoft Peel consists of round wax beads that provide a gentle and mild exfoliation. Mainly derived from natural and renewable resources, Cegesoft Peel is a readily biodegradable and environmentally friendly alternative to sharp-edged abrasives and non-degradable beads (often referred to as microplastic beads).
Hyalurosmooth – counteracting harmful effects of daily stress
Daily stresses are known to translate into cutaneous stress, with cortisol as its main mediator. Hyalurosmooth represses the damaging impact of cortisol on the skin, restoring collagen type I and hyaluronic acid that are affected. Bringing the positive effects of a mindful lifestyle – rested from the inside – Hyalurosmooth helps the skin recover its hydration and radiance. Extracted from the Indian Cassia angustifolia, Hyalurosmooth is IECIC-listed.
As part of the Inspire presentation program, Axel Boettcher from BTC Europe will be presenting new data on Hyalurosmooth.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance